Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Osmotica Pharmaceuticals Plc (OSMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 210,206
  • Shares Outstanding, K 51,521
  • Annual Sales, $ 263,700 K
  • Annual Income, $ -109,400 K
  • 60-Month Beta N/A
  • Price/Sales 0.79
  • Price/Cash Flow 1.28
  • Price/Book 0.54
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.99
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/27/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.11
  • Low Estimate -0.29
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.54 +15.25%
on 03/29/19
6.93 -41.13%
on 03/27/19
-2.23 (-35.34%)
since 03/18/19
3-Month
3.54 +15.25%
on 03/29/19
8.45 -51.72%
on 01/23/19
-4.12 (-50.24%)
since 01/18/19

Most Recent Stories

More News
Robbins Arroyo LLP is Investigating the Officers and Directors of Osmotica Pharmaceuticals plc (OSMT) on Behalf of Shareholders

Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) violated federal securities law....

OSMT : 4.08 (+1.24%)
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Osmotica Pharmaceuticals plc Investors

Law Offices of Howard G. Smithannounces an investigation on behalf of Osmotica Pharmaceuticals plc investors ("Osmotica" or the "Company") (NASDAQ:OSMT) concerning the Company and...

OSMT : 4.08 (+1.24%)
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Osmotica Pharmaceuticals plc Investors (OSMT)

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (NASDAQ: OSMT) investors concerning the Company and...

OSMT : 4.08 (+1.24%)
Lifshitz & Miller LLP Announces Investigation of Amyris, Inc., iRhythm Technologies, Inc., Orion Group Holdings, Inc., Osmotica Pharmaceuticals plc, Quantenna Communications, Inc., WABCO Holdings, Inc. and Zafgen, Inc.

Amyris, Inc. (AMRS)

QTNA : 24.28 (+0.25%)
AMRS : 5.02 (+20.10%)
WBC : 133.00 (+0.05%)
IRTC : 68.92 (+0.75%)
ORN : 2.71 (unch)
ZFGN : 2.59 (-3.00%)
OSMT : 4.08 (+1.24%)
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Osmotica Pharmaceuticals plc Investors (OSMT)

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (NASDAQ: OSMT) investors concerning the Company and...

OSMT : 4.08 (+1.24%)
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Osmotica Pharmaceuticals plc Investors

Law Offices of Howard G. Smithannounces an investigation on behalf of Osmotica Pharmaceuticals plc investors ("Osmotica" or the "Company") (NASDAQ:OSMT) concerning the Company and...

OSMT : 4.08 (+1.24%)
SHAREHOLDER ALERT: Investigation of Osmotica Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC is investigating whether certain statements made by Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (NASDAQ: OSMT) complied with federal securities laws. On...

OSMT : 4.08 (+1.24%)
Osmotica Pharmaceuticals plc Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress

Reported fourth quarter and full year 2018 total revenue of $65.7 million and $263.7 million, respectively

OSMT : 4.08 (+1.24%)
Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2018 Business and Financial Update on March 27, 2019

Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release its 2018 fourth quarter and full year...

OSMT : 4.08 (+1.24%)
Osmotica Pharmaceuticals Appoints Seasoned Financial Executive Gregory Cowan to Board of Directors and Audit Committee

Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Gregory Cowan, a seasoned financial executive with almost 40...

OSMT : 4.08 (+1.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade OSMT with:

Business Summary

Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women's health. The company's product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R)...

See More

Key Turning Points

2nd Resistance Point 4.15
1st Resistance Point 4.11
Last Price 4.08
1st Support Level 4.04
2nd Support Level 4.01

See More

52-Week High 9.90
Fibonacci 61.8% 7.47
Fibonacci 50% 6.72
Fibonacci 38.2% 5.97
Last Price 4.08
52-Week Low 3.54

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar